Management team

Management team

Andreas Bhagwani

Born 1975
CEO since 2011

andreas.bhagwani@nanologica.com

Education and training:

MBA from Stockholm School of Economics, studies in agronomy at the Swedish University of Agricultural Sciences in Uppsala.

Main experience:

Andreas is the co-founder of several companies, the most recent being Sigrid Therapeutics AB (obesity therapy) and Atrogi AB (diabetes). Andreas has worked as a management consultant for over a decade, specializing in sales and leadership. In addition to the above companies, he is a co-founder of WideNarrow, Kichisaga Leadership (management consultancy) and GenderTimer (cell phone app).

Other assignments:

CEO of Nanghavi AB. Board member and owner of Vega Bianca AB. CEO and chairman of the board of Nanologica Black AB and Nanologica Yellow AB. Board member of Nanghavi AB and Nanghavi Chromatography Solutions, deputy board member and co-owner of Kichisaga Leadership AB, as well as co-owner of Atrogi AB and Sigrid Therapeutics AB.

Holdings:

Holds 2,019,764 shares through the company Vega Bianca AB and 165,000 options.

Eva Osterman

Born 1971
CFO since 2017

eva.osterman@nanologica.com

Education and training:

Master of Science in Business Administration and Economics from Uppsala University.

Main experience:

Eva has many years of experience in finance at larger companies. She has worked within business control, financial control, reporting and internal audit. She also has extensive experience from major international firms in the pharmaceutical industry.

Other assignments:

Board member of Nanghavi Chromatography Solutions Private Limited and Nanologica Australia Pty. Ltd, deputy board member of Nanghavi AB, Nanologica Black AB, Nanologica Yellow AB and Consensor AB.

Holdings:

Holds 49,783 shares. and 60,000 options.

Anna-Karin Renström

Born 1964

Director Operations and Strategies since 2019              

EDUCATION AND TRAINING:

MSHc Industrial Engineering and Management, Business Performance Diploma and Executive Management Program, Stockholm School of Economics, Certification in Board work, Styrelsekraft via ALMI

MAIN EXPERIENCE:

Anna-Karin was the CEO of Telge Inköp for 10 years before joining Nanologica. She has also held the positions as Chairman of Telge Kraft AB and board member at Telge Nät AB. Before that she worked in various positions within purchasing and finance at AstraZeneca.

OTHER ASSIGNMENTS:

No other assignments.

HOLDINGS:

Holds 48,483 shares and 60,000 options.

Gary Pitcairn, CSO Nanologica

Gary Pitcairn

Born 1967
Chief Scientific Officer since 2021
              

EDUCATION AND TRAINING:

BSc Biochemistry and Biological Chemistry, Univeristy of Nottingham. PhD University of Nottingham.

MAIN EXPERIENCE:

Gary is a recognised expert in inhaled drug delivery, with extensive device experience (DPI, pMDI and nebuliser). He has formerly worked at Mylan, Pfizer and most recently AstraZeneca where he was Head of Project Leadership – Respiratory Pharmaceutical Technology & Development.

OTHER ASSIGNMENTS:

Board member of Nanologica Australia Pty. Ltd and GRP Consulting AB. 

HOLDINGS:

Holds no shares or options. 

Ulf Ericsson, VP Drug Development Nanologica

Ulf Ericsson

Born 1966
VP Drug Development since 2021

Education and training:

Master of Science in Business Administration, Business Economics (BSc) and Marketing Management (MSc), Lund University

Main experience:

Ulf has more than 20 years’ experience from leading Marketing and Business Development positions within the inhaled respiratory therapeutic area, whereof the last 17 years at AstraZeneca where he was the Global Sr Director Respiratory Inhalation. Ulf has extensive experience in inhalation devices and formulation technologies.

Other assignments:

No other assignments.

Holding:

Holds no shares or options.